Kraig Biocraft Laboratories annual stock-based compensation
2010
2011
2012
2013
2022
2023
2024
2025
Kraig Biocraft Laboratories Stock-Based Compensation Growth & History (KBLB)
Kraig Biocraft Laboratories's stock-based compensation was $87,285 for fiscal 2025.
View full Kraig Biocraft Laboratories company overviewKraig Biocraft Laboratories annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $87,285 | $87,285 | — |
| 2024 | 2024-12-31 | $0 | −$225,000 | — |
| 2023 | 2023-12-31 | $225,000 | $225,000 | — |
| 2022 | 2022-12-31 | $0 | — | — |
| 2013 | 2013-12-31 | $0 | −$550,000 | — |
| 2012 | 2012-12-31 | $550,000 | $238,000 | +76.28% |
| 2011 | 2011-12-31 | $312,000 | −$102,000 | −24.64% |
| 2010 | 2010-12-31 | $414,000 | — | — |
Kraig Biocraft Laboratories quarterly stock-based compensation
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q3.13
Q3.14
Q3.15
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $29,085 | — | — |
| Q1 2026 | 2026-03-31 | $29,085 | — | — |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q3 2025 | 2025-09-30 | $29,095 | — | — |
| Q3 2015 | 2015-09-30 | $0 | $0 | — |
| Q3 2014 | 2014-09-30 | $0 | $0 | — |
| Q3 2013 | 2013-09-30 | $0 | $0 | — |
| Q1 2013 | 2013-03-31 | $0 | $0 | — |
| Q4 2012 | 2012-12-31 | $40,000 | −$202,000 | −83.47% |
| Q3 2012 | 2012-09-30 | $0 | $0 | — |
| Q2 2012 | 2012-06-30 | $510,000 | $440,000 | +628.57% |
| Q1 2012 | 2012-03-31 | $0 | $0 | — |
| Q4 2011 | 2011-12-31 | $242,000 | — | — |
| Q3 2011 | 2011-09-30 | $0 | −$409,000 | — |
| Q2 2011 | 2011-06-30 | $70,000 | — | — |
| Q1 2011 | 2011-03-31 | $0 | — | — |
| Q3 2010 | 2010-09-30 | $409,000 | — | — |
Kraig Biocraft Laboratories stock-based compensation trends
Between the periods ended 2010-12-31 and 2025-12-31, Kraig Biocraft Laboratories's stock-based compensation decreased from $414,000 to $87,285, a change of −$326,715. The latest reported quarter, Q2 2026, shows $29,085.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kraig Biocraft Laboratories source filings ↗